These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12562311)

  • 41. Flagellin as carrier and adjuvant in cocaine vaccine development.
    Lockner JW; Eubanks LM; Choi JL; Lively JM; Schlosburg JE; Collins KC; Globisch D; Rosenfeld-Gunn RJ; Wilson IA; Janda KD
    Mol Pharm; 2015 Feb; 12(2):653-62. PubMed ID: 25531528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.
    Wenthur CJ; Cai X; Ellis BA; Janda KD
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3666-3668. PubMed ID: 28709828
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimization of a methamphetamine conjugate vaccine for antibody production in mice.
    Stevens MW; Gunnell MG; Tawney R; Owens SM
    Int Immunopharmacol; 2016 Jun; 35():137-141. PubMed ID: 27039212
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Further ethical and social issues in using a cocaine vaccine: response to Hall and Carter.
    Ashcroft RE; Franey C
    J Med Ethics; 2004 Aug; 30(4):341-3. PubMed ID: 15289513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-cocaine Vaccine Development: Where Are We Now and Where Are We Going?
    Stephenson RJ; Toth I
    J Med Chem; 2023 Jun; 66(11):7086-7100. PubMed ID: 37227096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploring the feasibility of an anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2beta anti-idiotypic antibodies.
    Schabacker DS; Kirschbaum KS; Segre M
    Immunology; 2000 May; 100(1):48-56. PubMed ID: 10809958
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage.
    Gao Y; Geng L; Orson F; Kinsey B; Kosten TR; Shen X; Brimijoin S
    Chem Biol Interact; 2013 Mar; 203(1):208-11. PubMed ID: 22935511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current challenges for the creation of effective vaccines against drugs of abuse.
    Moreno AY; Janda KD
    Expert Rev Vaccines; 2011 Dec; 10(12):1637-9. PubMed ID: 22085165
    [No Abstract]   [Full Text] [Related]  

  • 49. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans.
    Haney M; Gunderson EW; Jiang H; Collins ED; Foltin RW
    Biol Psychiatry; 2010 Jan; 67(1):59-65. PubMed ID: 19846066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of a therapeutic cocaine vaccine in rodent models.
    Fox BS; Kantak KM; Edwards MA; Black KM; Bollinger BK; Botka AJ; French TL; Thompson TL; Schad VC; Greenstein JL; Gefter ML; Exley MA; Swain PA; Briner TJ
    Nat Med; 1996 Oct; 2(10):1129-32. PubMed ID: 8837612
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Substance abuse vaccines.
    Orson FM; Kinsey BM; Singh RA; Wu Y; Gardner T; Kosten TR
    Ann N Y Acad Sci; 2008 Oct; 1141():257-69. PubMed ID: 18991962
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of immunopharmacotherapy against drugs of abuse.
    Meijler MM; Matsushita M; Wirsching P; Janda KD
    Curr Drug Discov Technol; 2004 Jan; 1(1):77-89. PubMed ID: 16472221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [New developments in the pharmacotherapy of cocaine dependence].
    Wiesbeck G; Dürsteler-MacFarland K
    Nervenarzt; 2006 Sep; 77(9):1064, 1066-70. PubMed ID: 16425053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs.
    Hicks MJ; De BP; Rosenberg JB; Davidson JT; Moreno AY; Janda KD; Wee S; Koob GF; Hackett NR; Kaminsky SM; Worgall S; Toth M; Mezey JG; Crystal RG
    Mol Ther; 2011 Mar; 19(3):612-9. PubMed ID: 21206484
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A second-generation vaccine protects against the psychoactive effects of cocaine.
    Carrera MR; Ashley JA; Wirsching P; Koob GF; Janda KD
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1988-92. PubMed ID: 11172063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion.
    Carroll ME; Zlebnik NE; Anker JJ; Kosten TR; Orson FM; Shen X; Kinsey B; Parks RJ; Gao Y; Brimijoin S
    PLoS One; 2012; 7(8):e43536. PubMed ID: 22912888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Animal Models and the Development of Vaccines to Treat Substance Use Disorders.
    Ohia-Nwoko O; Kosten TA; Haile CN
    Int Rev Neurobiol; 2016; 126():263-91. PubMed ID: 27055616
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anticocaine catalytic antibodies have no affinity for RTI compounds: implications for treatment.
    Kuhar MJ; Carroll FI; Bharat N; Landry DW
    Synapse; 2001 Aug; 41(2):176-8. PubMed ID: 11400184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of a recombinant humanized anti-cocaine monoclonal antibody produced from multiple clones for the selection of a master cell bank candidate.
    Wetzel HN; Webster RP; Saeed FO; Kirley TL; Ball WJ; Norman AB
    Biochem Biophys Res Commun; 2017 Jun; 487(3):690-694. PubMed ID: 28442345
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccine development against methamphetamine drug addiction.
    Hossain MK; Hassanzadeganroudsari M; Nurgali K; Apostolopoulos V
    Expert Rev Vaccines; 2020 Dec; 19(12):1105-1114. PubMed ID: 33251859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.